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Abstract
PURPOSE: Tumors encounter endoplasmic reticulum stress during tumor growth and activate an adaptive pathway
known as the unfolded protein response (UPR). Because this pathway is induced by the tumor microenvironment,
it is a promising target for cancer therapy. We have previously demonstrated that X-box binding protein 1 (XBP-1), a
key regulator of the UPR, was required for survival under hypoxia and critical for tumor growth in tumor xenografts.
In this study, we investigated the role of XBP-1 in regulating tumor angiogenesis. METHODS: We used an intra-
dermal angiogenesis model to quantify the effect of XBP-1 on angiogenesis. We also used a human tumor xeno-
graft model to assay for tumor growth delay. We determined vascular endothelial growth factor (VEGF) expression
by quantitative polymerase chain reaction and ELISA. Finally, we stained human pancreatic adenocarcinoma speci-
mens for XBP-1 expression and correlated the expression pattern of XBP-1 with CD31 (endothelial cell marker)
expression. RESULTS: We demonstrated that XBP-1 is essential for angiogenesis during early tumor growth. Inhibit-
ing XBP-1 expression by short-hairpin RNA sequence specific for XBP-1 reduced blood vessel formation in tumors
from mouse embryonic fibroblast cells and human fibrosarcoma tumor cells (HT1080). Expressing a dominant-
negative form of IRE1α also reduced blood vessel formation in tumors. Moreover, expression of spliced XBP-1
(XBP-1s) restored angiogenesis in IRE1α dominant-negative expressing cells. We further demonstrated that XBP-
1–mediated angiogenesis does not depend on VEGF. CONCLUSIONS: We propose that the IRE1α–XBP-1 branch of
the UPR modulates a complex proangiogenic, VEGF-independent response that depends on signals received from
the tumor microenvironment.
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Introduction
Tumors experience hypoxia and endoplasmic reticulum (ER) stress
during growth when the energy demands exceed the capacity of the
vasculature to supply nutrients. Under these pathophysiological condi-
tions, activation of the unfolded protein response (UPR) triggers an
adaptive pathway that allows cells to survive in this microenvironment
characterized by hypoxia, low glucose, and low pH. Inhibiting the
UPR under these conditions is a promising therapeutic strategy [1,2].
We have previously demonstrated that the IRE1-XBP1 branch of
the UPR mediated survival under hypoxia and was essential for tumor
growth. Transformed mouse embryonic fibroblasts (MEFs) [3] or
human fibrosarcoma tumor cells (HT1080) [4] that are deficient in
X-box binding protein 1 (XBP-1) are impaired in their ability to grow
as tumor xenografts in SCID mice. Similarly, PKR-like ER kinase
(PERK), another branch of the UPR responsible for attenuation of
protein translation during hypoxia and ER stress, also plays an impor-
tant role in regulating tumor growth [5,6]. Both PERK and XBP-1–
deficient cells showed increased apoptosis and decreased clonogenic
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survival during ER stress/hypoxia. These findings strongly suggest that
the UPR represents an important signaling pathway that is critical for
tumor growth.
UPR target genes are expressed in a variety of human tumors [7]
and have important implications in cancer therapy [8,9]. XBP-1 has
been reported to be overexpressed in breast cancer [10], hepatocel-
lular carcinoma [11], and colorectal cancer [12]. In this study, we
investigated the role of XBP-1 in regulating tumor angiogenesis.
Materials and Methods
Cell Culture and Hypoxia Treatments
MEF and human HT1080 fibrosarcoma cells were maintained in
Dulbecco’s modified Eagle’s medium supplemented with fetal bovine
serum (10%) at 37°C in a 5% CO2 incubator. For the hypoxia ex-
periments, cells were treated at 70% to 80% confluency and main-
tained in an anaerobic chamber (Sheldon Corp., Cornelius, OR) with
PO2 levels <0.02%.
Constructs, Reporter Assays, and Production of Stably
Expressing Cells
Human XBP-1–specific sequence (5′-GCTCTTTCCC TCATG-
TATACT-3′) was used for short-hairpin RNA (shRNA) and cloned in
pSIREN-RetroQ vector (Clontech, Mountain View, CA). We used
the following sequences as shRNA controls: scrambled (SC; 5′-CA-
CATGTTCCGATCTCGGC-3′), nontarget sequence obtained from
Sigma-Aldrich, St. Louis, MO (NT; 5′-CAACAAGATGAAGAGC-
ACCAA-3′), green fluorescent protein sequence (GFP; 5′-TACAA-
CAGCCACAACGTCTAT-3′), and a sequence with four mismatches
of the human XBP-1–specific sequence (MM; 5′-GCTgTaTgCCTg-
ATGTATACT-3′).
Additional details are available in Supplementary Material. A flag-
tagged dominant-negative form of IRE1α and the XBP-1 spliced form
(XBP-1s) was cloned into pBabe-Puromycin and pWZL-hygromycin
retroviral vectors, respectively. Infected cells were selected with hygro-
mycin (375 μg/ml) or puromycin (1 μg/ml) for 10 days. The expres-
sion of XBP-1 was confirmed by Western blot analysis, quantitative
polymerase chain reaction (qPCR), and the UPRE-Luciferase reporter
assay techniques as described below. HT1080 cells (1.5 × 105) were
cultured in 12-well plates. The next day, cells were cotransfected with
a pGL3-5×UPRE-luc (containing five repetitions of the XBP-1 DNA
binding site), and a plasmid containing the β-galactosidase enzyme
was used for transfection efficiency. All data were normalized by β-
galactosidase activity and expressed as a ratio of luciferase/β-galactosidase
activity. All results were normalized to the control whose value was
arbitrarily set to 1. Lipofectamine and Plus reagent were used accord-
ing to the manufacturer’s protocol (Invitrogen, Carlsbad, CA). Lucif-
erase assay kit and β-galactosidase assay kit were used according to
the manufacturer’s protocol (Promega, San Luis Obispo, CA).
Western Blot Analysis
Cell extracts were prepared in 9 M urea–75 mM Tris-HCl (pH 7.5)
and 0.15 M β-mercaptoethanol (Sigma, St. Louis, MO), sonicated
briefly, boiled at 95°C for 5 minutes, and loaded onto SDS-PAGE gels.
After electrophoresis, the proteins were transferred onto a nitrocellu-
lose membrane (Bio-Rad, Hercules, CA) and blocked in 5% nonfat
milk with 0.1% Tween-20 in Tris-buffered saline for 30 minutes at
room temperature. An affinity-purified rabbit polyclonal antibody,
generated against a peptide fragment specific for human XBP-1s, was
used at 1:1000 dilution or a rabbit polyclonal antibody from Biolegend
(San Diego, CA) at 1:500 dilution. A monoclonal β-actin antibody
(1:3000; Sigma) was used for loading control. After incubation with
the primary antibody, the membranes were washed and hybridized
with peroxidase-conjugated IgG antibodies (Jackson Immunoresearch,
West Grove, PA) as secondary antibodies. The blots were devel-
oped with enhanced chemoluminiscence (ECL) substrate (Amersham,
Piscataway, NJ).
Quantitative PCR
Total RNA was extracted from cultured cells using TRIzol reagent.
The cDNA was synthesized from 2 μg of total RNA using Superscript
III Reverse Transcriptase kit (Invitrogen) according to the manufac-
turer’s protocol. The cDNAwas subjected to qPCR on an ABI PRISM
7900HT (Applied Biosystems, Foster City, CA) using SYBR Green
PCR Kit. PCR amplifications were performed with specific primers
in a total volume of 10 μl containing 1 μl of sense and antisense
primer mixture (5 μM of each primer), 5 μl of 2xSYBR Green QPCR
Master Mix (Applied Biosystems), 1 μl of diluted cDNA and nuclease-
free PCR-grade water. The mixture was used as a template for the
amplification after initial denaturation at 95°C and 40 cycles (95°C
for 30 seconds, 60°C for 1 minute, and 72°C for 30 seconds). Prim-
ers sequences used were as follows: for human XBP-1, 5′-AGCCA-
AGGGGAATGAAGTGA-3′ (sense) and 5′-GGGGAAGGGCAT
TTGAAGAA-3′ (antisense); for mouse XBP-1, 5′-TCCGCAGCAC-
TCAGACTATG -3′ (sense) and 5′-ACAGGGTCCAACTTGTC-
CAG-3′ and for human VEGF 5′-ATCTTCAAGCCATCCTGTGT-
GC-3′ (sense) and 5′-GCTCACCGCCTCGGCTTGT-3′ (antisense).
SYBR Green fluorescence was measured, and quantification of each
PCR product was expressed relative to beta-actin or 18S rRNA.
Angiogenesis Assay In Vivo
Each SCID mouse was implanted intradermally on the ventral
surface with four tumors symmetrically equidistant as described by
Danielsen and Rofstad [13]. Cells (1 × 105 for MEF cells and 2 ×
105 for HT1080 cells) were injected in a volume of 10 μl together
with one drop of 0.4% trypan blue to visualize the sites of injection.
After 3 and 6 days for MEF cells or after 7 days for HT1080 cells,
the mice were killed, the skin carefully separated, and the number of
vessels reaching the edge of the tumor was scored by independent
observers blinded to the treatment group with the use of a dissecting
microscope at 15× magnification. Results from different controls for
shRNA are included in Supplementary Material. Uninfected parental
HT1080 cells were used as an additional control.
VEGF Secretion Assay
Cells (4 × 105) were seeded in 6-cm dishes and incubated over-
night. Fresh media were added, and cells were exposed to 24 hours
of normoxia or hypoxia (O2 < 0.02%). VEGF was measured by
ELISA according to the manufacturer’s protocol (R&D Systems,
Indianapolis, IN).
Immunohistochemical Staining
The immunohistochemical stains were performed using an affinity-
purified rabbit polyclonal antibody, generated against a peptide frag-
ment specific for human XBP-1s antibody directed against human
XBP-1. Serial sections of 4 μm were obtained from the selected par-
affin blocks, deparaffinized in xylene, and hydrated in a graded series
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of alcohol. Heat-induced antigen retrieval was carried out by micro-
wave pretreatment in citric acid buffer (10 mM, pH 6.0) for 10 min-
utes. The XBP-1s antibody was used at a dilution of 1:1000, and the
tissue was incubated at room temperature for 30 minutes. The en-
dogenous peroxidase was blocked, and the DAKO Envision system
(DAKO Corporation, Carpinteria, CA) was used for detection. A tis-
sue microarray of formalin-fixed paraffin-embedded normal and car-
cinoma tissues was used for initial titration of the XBP-1 antibody.
On the basis of these results, colon carcinoma was selected as a positive
control, and normal colon mucosa was used as a negative control. The
XBP-1 staining was scored semiquantitatively in the invasive carci-
noma, stroma within the carcinoma, and nonneoplastic pancreas as
follows: 0, no staining; 1+, weak and focal (<10% of lesional cells posi-
tive); 2+, patchy weak or strong staining (10-30% of lesional cells posi-
tive); 3+, strong and diffuse (>30% of lesional cells positive).
Results
XBP-1 Is Essential for Tumor Angiogenesis in MEF Cells
and in Human Fibrosarcoma HT1080 Cells
We have previously demonstrated that constitutive XBP-1 deficiency
impairs tumor growth in human and mouse cell lines [3,4]. In this
study, we used an intradermal angiogenesis assay [13] to determine
the role of XBP-1 on tumor angiogenesis. We expressed a shRNA se-
quence to inhibit XBP-1 expression (Figure 1A) in mouse embryonic
fibroblasts (shXBP-1 MEF) and found that their growth as tumor
xenografts were impaired compared with the control cells (Figure 1B).
The impaired growth of the tumor xenografts expressing shXBP-1
is consistent with the decreased expression of XBP-1 observed in
these cells. After implanting these cells intradermally, shXBP-1MEF
cells showed significantly less blood vessel formation than the control
cells (shControl MEF; Figure 1C). In these studies, we implanted 1 ×
105 cells and had two independent observers score the number of tu-
mor capillaries for each tumor using a dissection microscope. Each ob-
server was blinded to the cell type for each tumor. We also performed
the same experiments in a human fibrosarcoma cell line (HT1080).
As shown in Figure 2A (right panel ), the shXBP-1HT1080 cells had
significantly less XBP-1 protein expression under hypoxic conditions
than the control cells. Similarly, using an XBP-1 responsive reporter
construct (5×-UPRE-luciferase), cells inhibited in XBP-1 expression
also showed less XBP-1–dependent reporter transactivation after treat-
ment with tunicamycin, an inhibitor of glycosylation (Figure 2A, left
panel ). Overall, the number of capillaries was significantly reduced
in shXBP-1HT1080 cells compared with the control shSC-HT1080
cells (Figure 2, B and C , and Figure W2). There was no difference
in cell proliferation between these cell lines when assayed for growth
in cell culture (data not shown). As additional controls to rule out
the possibility of “off-target” effects of XBP-1 shRNA, we compared
the blood vessel formation of shXBP-1HT1080 cells with several
HT1080 control cells expressing a scrambled shRNA sequence, a 4-bp
Figure 1. XBP-1 is essential for tumor angiogenesis in MEF cells. (A) Reduction of XBP-1 expression by a short-hairpin specific sequence
was verified by qPCR for total XBP-1 messenger. (B) Tumor growth data from XBP-1 control MEF cells (shControl MEF) and XBP-1
shRNA–expressing cells (shXBP-1 MEF). Each SCID mouse was implanted subcutaneously with two tumors consisting of 2 ×
106 shControl MEF cells in one flank and 2 × 106 shXBP-1 MEF cells in the contralateral flank. Error bars, SD of the mean from four
tumors. (C) Angiogenesis assay in vivo for XBP-1 control MEF cells (shControl MEF) and XBP-1 shRNA–expressing cells (shXBP-1 MEF).
SCID mice were intradermally implanted with 1 × 105 MEF cells. The number of vessels growing into the tumor was scored 3 and
6 days after implantation with each observer blinded to the treatment condition. Error bars, SE of the mean from at least six tumors.
Statistical significance was determined using a 2-tailed t test.
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mismatch of the original knockdown sequence, a non target shRNA se-
quence, a GFP shRNA sequence, and uninfected HT1080 parental cells
(Figure 2B and Figure W2). Functionally, only the shXBP-1HT1080
cells were able to block transactivation of an XBP-1–dependent re-
porter construct (UPRE-luciferase; Figure W1). We have previously
demonstrated that HT1080 cells expressing XBP-1 shRNA are inhib-
ited in tumor growth compared with control HT1080 cells [14]. Col-
lectively, these studies demonstrate that specific inhibition of XBP-1
results in decreased tumor growth and decreased angiogenesis.
IRE1α Is Essential for Tumor Angiogenesis in HT1080 Cells
XBP-1 protein has two isoforms that are expressed from the same
mRNA: an unspliced (XBP-1u) and spliced form (XBP-1s). Under hyp-
oxia andER stress conditions, XBP-1mRNA is spliced by the ERprotein
IRE1α. To determine the role of IRE1α on angiogenesis, we over-
expressed a truncated version of this protein that contained only the car-
boxy terminus. Expression of this dominant-negative form of IRE1α
inhibited the induction of XBP-1 splicing under hypoxia (Figure 3A).
Using the same intradermal angiogenesis assays, cells expressing this
dominant-negative form of IRE1α (HT1080-IΔC), also demonstrated
fewer capillaries than control cells (HT1080-pBabe; Figure 3B). Because
IRE1α is required for XBP-1 splicing, these results suggest a key role
for both IRE1α and spliced XBP-1 in tumor angiogenesis.
XBP-1s Restores Tumor Angiogenesis in IRE1α
Dominant-Negative Expressing Cells
We generated additional HT1080 cell lines expressing dominant-
negative IRE1α alone (ΔC), spliced XBP-1 alone (S), or both simul-
taneously (ΔCS). Spliced XBP-1 expression was confirmed by Western
blot analysis with an antibody that only recognizes the spliced form
(Figure 4A, top panel, lanes 3, 4, 7, and 8). Dominant-negative IRE1α
expression (Flag-tagged) was confirmed with anti-Flag antibody (Fig-
ure 4A, lower panel, lanes 2, 3, 6, 7 ). As expected in control cells,
tunicamycin induced XBP-1 splicing (compare top panel, lane 1 vs 5),
Figure 2. XBP-1 is essential for tumor angiogenesis in HT1080 cells. Reduction of XBP-1 expression by a short-hairpin specific sequence
was verified by (A) UPRE reporter assay (left panel) and Western blot analysis for spliced XBP-1 (XBP-1s–specific antibody, right panel).
Cells were exposed to 8 hours of tunicamycin (5 μg/ml for 8 hours) for the reporter assays and 24 hours of hypoxia (O2 < 0.02%) for the
Western blot analysis to induce XBP-1 splicing. Expression of β-actin is included as a loading control. (B) Angiogenesis assay in vivo for
XBP-1 scramble control HT1080 cells (shSc-HT1080) and XBP-1 shRNA–expressing cells (shXBP-1HT1080). SCID mice were intrader-
mally implanted with 2 × 105 HT1080 cells. The number of vessels growing into the tumor was scored 7 days after implantation. Each
observer quantitated the number of blood vessels independently and was blinded to the treatment condition. Error bars, SE of the mean
from at least 10 tumors. Statistical significance was determined using a 2-tailed t test. (C) Representative photomicrographs of the tumors
from angiogenesis assays. As shown in the bottom panel, there are significantly fewer capillaries growing into the HT1080 tumors with
reduced XBP-1 expression (sh-XBP-1HT1080) compared with the scrambled shRNA control–expressing cells (top panel, shSCHT1080).
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and XBP-1 splicing was blocked when dominant-negative IRE1α was
expressed (compare top panel, lane 2 vs 6). Figure 4B shows that an XBP-
1–responsive reporter construct (5×-UPRE-luciferase) was blocked by
dominant-negative IRE1α expression (middle columns) and that this
inhibition can be overcome with overexpression of spliced XBP-1 ( far
right columns). And finally, HT1080 cells expressing dominant-negative
IRE1α (HT1080dvector-ΔC) demonstrated reduced blood vessel for-
mation compared with the control cells (HT1080dvector-φ). However,
cells coexpressing dominant-negative IRE1α and spliced XBP-1
(HT1080dvector-ΔCS) restored angiogenesis to similar levels as the
control cells (HT1080dvector-φ; Figure 4C ). Next, we determined
whether XBP-1 expression influenced VEGF expression in these cells.
Using qPCR, we did not observe any difference in either basal VEGF
expression or hypoxic induction of VEGF expression between HT1080
control cells (shSC-HT1080) and HT1080 cells expressing an XBP-1
shRNA construct (shXBP-1HT1080; Figure 4D). Similar findings were
noted for SU86.86 cells, a human pancreatic cancer cell line. VEGF pro-
tein secretion was also not significantly different between these cell lines
under normoxic and hypoxic conditions (FigureW3). These studies sug-
gest that although XBP-1s plays an important role in angiogenesis, the
regulation of this process occurs independently of VEGF.
XBP-1 Expression in Human Pancreatic Tumors Correlates
with CD31 Expression
Because of the inherent limitations of the animal models of angio-
genesis used, we further extended our studies of XBP-1s–mediated
angiogenesis in a defined set of human pancreatic tumors. We stained
32 consecutive human pancreatic adenocarcinoma resection specimens
(mucinous tumors excluded) for spliced XBP-1 and CD31 (endothe-
lial cell marker) expression. In general, the XBP-1s staining was specific
for the tumor cells, whereas the CD31 staining tended to localize to
the tumor stromal cells. Neither did we find a correlation between
pancreatic tumor size and XBP-1s expression nor did we observe a cor-
relation between CD31 staining and pancreatic tumor size. Table 1
shows the pathologic characteristics of the pancreatic tumor samples
used in this study. A board-certified pathologist (N.K.) scored the in-
tensity of XBP-1s staining in these sections as follows: 0 (no expres-
sion), 1 (weak expression), 2 (moderate expression), and 3 (strong
expression). On consecutive sections, these specimens were also as-
sessed for CD31 staining. Shown in Figure 5A are representative stain-
ing of two adjacent pancreatic tumor sections showing high XBP-1s
expression from the tumor cells with high CD31 staining from the ad-
jacent stroma. CD31-positive blood vessels were counted at 300× mag-
nification from three different areas within each tumor, and a mean
CD31 score was determined for each tumor. We found a significant cor-
relation between XBP-1 staining and mean CD31 score within these
tumors. Specifically, the group of patients with mod-strong XBP-1s ex-
pression had higher CD31 scores than those patients with neg-weak
XBP-1s expression (Figure 5B). These results indicate that XBP-1 ex-
pression in human pancreatic tumors is clinically relevant to angiogen-
esis and suggests a therapeutic opportunity in treating this disease.
Discussion
We have previously reported that human pancreatic tumors are
extremely hypoxic as determined by intraoperative measurements
using a polar graphic microelectrode technique [15]. What remains
unclear is whether tumor angiogenesis occurs as a response to tumor
hypoxia or whether tumor hypoxia is a consequence of insufficient
angiogenesis. Most likely, within human tumors, both processes occur
and a dynamic interplay exists between the tumor microenvironment
and angiogenesis. The ultimate consequence of this interaction is
tumor growth.
In prior studies, we found that XBP-1 was a critical mediator of
tumor growth, and the data from the current study support the hy-
pothesis that at least part of the mechanism for impaired growth of
XBP-1 deficient tumors was through decreased angiogenesis. Our
previous study demonstrated that VEGF secretion was not signifi-
cantly different between XBP-1 wild-type and knockout MEFs [3],
suggesting that VEGF does not play a direct role in XBP-1–regulated
angiogenesis. In the current study, we also did not observe any sig-
nificant differences in VEGF expression in two different tumor cell
lines (HT1080, human fibrosarcoma, and SU.86.86, human pancre-
atic cancer) expressing shRNA constructs to block XBP-1 (Figure 4D
and Figure W3). However, angiogenesis is a complex sequence of
events, and up-regulation of other proangiogeneic factors as well as
down-regulation of antiangiogeneic factors also plays an important
role. With regards to other UPR signaling pathways, PERK has also
been implicated in tumor growth and angiogenesis [16]. Interest-
ingly, VEGF secretion also was not regulated in a PERK-dependent
manner [5].
Figure 3. A dominant-negative form of IRE1α inhibits angiogenesis in HT1080 cells. (A) Western blot for spliced XBP-1 (XBP-1s), Flag-
tagged IRE1α dominant-negative protein (IΔC), and β-actin (as loading control). Cells were treated with 24 hours of hypoxia (O2 < 0.02%)
to induce XBP-1 splicing. There was no XBP-1 splicing in the IRE1α dominant-negative expressing cells. (B) Angiogenesis assay in vivo
for empty vector control cells (HT1080-pBabe) and flag-tagged IRE1α dominant-negative expressing cells (HT1080-IΔC). Error bars, SE of
the mean from 10 tumors. Statistical significance was determined using a 2-tailed t test.
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The cytoplasmic portion of IRE1α contains both a kinase and an
endonuclease domain. Whereas the kinase domain is required for
the endonuclease activity of the protein, it can also activate the JNK
pathway through its interaction with TRAF2 [17]. The IRE1 endo-
nuclease is responsible for splicing XBP-1 and has also been shown
to degrade a set of target mRNA in Drosophila, including some mRNA
that encode for proteins involved in angiogenesis [18]. Drogat et al.
showed that in cell culture, tumor cells expressing a kinase inactive
mutant for IRE1α (IRE1αK599A) had decreased VEGFmRNA induc-
tion during relatively mild hypoxia (3% O2) or hypoglycemia [19]. Fur-
thermore, these investigators used an orthotopic glioma tumor model
Figure 4. XBP-1 spliced form (XBP-1s) rescues tumor angiogenesis in IRE1α dominant-negative expressing cells. (A) Expression of XBP-1s
and IRE1α dominant-negative in HT1080 cells was confirmed by Western blot analysis. Lanes 1 and 5 are HT1080 vector control cells.
Lanes 2 and 6 are HT1080 cells transfected with a Flag-tagged IRE1α dominant-negative construct. Lanes 3 and 7 are HT1080 cells trans-
fected with both Flag-tagged IRE1α dominant-negative construct and an XBP-1 overexpression construct. Lanes 4 and 8 are HT1080 cells
transfected with XBP-1 overexpression construct. Tunicamycin (5 μg/ml for 8 hours) was used to induce XBP-1 splicing. β-Actin was used
as a loading control. Western blot analysis was carried out using XBP-1s–specific antibody (Biolegend). (B) XBP-1 reporter (UPRE-luciferase)
assay in HT1080 cells expressing vector alone (vector-φ), IRE1α dominant-negative (vector-ΔC), or IRE1α dominant-negative and spliced
XBP-1 (ΔCS). All cells were treated with tunicamycin (5 μg/ml for 8 hours). Expression of IRE1α dominant-negative blocked transactivation
of the UPRE-luciferase reporter during tunicamycin treatment. Inhibition of the UPRE-luciferase reporter could be reversed by overexpres-
sion of XBP-1s. (C) Angiogenesis assay for HT1080 cells expressing vector alone (vector-φ), IRE1α dominant-negative (φ-ΔC), or IRE1α
dominant-negative and spliced XBP-1 (ΔCS). Error bars, SE of the mean from at least eight tumors. Statistical significance was determined
using a 2-tailed t test. (D) VEGF expression by qPCR in HT1080 control cells (shSC-HT1080) or HT1080 cells inhibited in XBP-1 expression
by shRNA (shXBP-1HT1080). There was no difference in VEGF expression at baseline or during hypoxia between these two cell lines.
Table 1. Pancreatic Adenocarcinoma Tumor Characteristics (n = 32).
Patients’ age (years), mean (range) 69 (43-85)
Tumor grade, n (%)
Well differentiated 7 (22)
Moderately differentiated 19 (59)
Poorly differentiated 6 (19)
Lymph node status, n (%)
Positive 16 (50)
Negative 16 (50)
Resection margin, n (%)
Positive 10 (31)
Negative 22 (69)
Tumor size (cm), median (range) 3.80 (1.10-6.00)
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to show that IRE1αK599A expressing tumors grew slower and showed
decreased blood vessel formation compared with control tumors.
Our data are consistent with these investigators and also demon-
strate that IRE1α plays an important role in angiogenesis. In both
tumor model systems, overexpression of a dominant-negative form
of IRE1α resulted in reduced blood vessel formation. Moreover, over-
expression of spliced XBP-1 was sufficient to overcome the effect of
IRE1α dominant-negative expression on angiogenesis. However, our
findings differ from Drogat et al. in that we did not observe any sig-
nificant differences in VEGF expression in two different cell lines in-
hibited in XBP-1 expression (Figure 4D and Figure W3). These results
suggest that VEGF expression may be altered depending on whether
XBP-1 or IRE1α is blocked. Another possibility is that these dif-
ferences may be accounted for by the different cell types used in
these experiments. Because the XBP-1 shRNA experiments blocked
expression of both the spliced and unspliced form of XBP-1, we can-
not exclude the possibility that the unspliced form of XBP-1 may also
contribute to angiogenesis. Although unspliced XBP-1 can function as
a negative regulator of spliced XBP-1 [20,21], it may also differentially
activate UPR target genes if its stability is altered [22].
Our results demonstrate that XBP-1 expression is important for
angiogenesis in a variety of tumor xenografts derived from multiple
different cell types including MEFs and HT1080 cells. These data
suggest that our results may be generally applied to multiple tumor
types. Moreover, we report a strong correlation between XBP-1 acti-
vation and increased vessel density from human pancreatic adeno-
carcinoma specimens, which strongly suggests that this pathway is
relevant in human cancer. And finally, although multiple factors
can affect tumor growth (proliferation, apoptosis, adaptation), angio-
genesis is an important component of the tumor microenvironment
that influence overall tumor growth kinetics. We propose that IRE1/
XBP-1 functions as part of a complex network of UPR signaling that
depends on the tumor microenvironment for the appropriate angio-
genic stimuli. These data have important implications in developing
antiangiogenic tumor treatment strategies in pancreatic cancers.
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Figure W2. Angiogenesis assays in HT1080 cells stably expressing different shRNA controls and a specific sequence for XBP-1. We used
HT1080 cells stably expressing a shRNA specific for XBP-1 (shXBP-1HT1080) and compared blood vessel formation in control cells ex-
pressing four different shRNA sequences: a scramble sequence (shSC-HT1080); a sequence with four mismatches from the original
shRNA specific for XBP-1 (shMM-HT1080); a nontarget sequence (shNT-HT1080); and a sequence from GFP (shGFP-HT1080). Uninfected
HT1080 parental cells were used as additional controls. Error bars, SE of the mean from 10 tumors.
Figure W1. UPRE reporter assays with HT1080 cells expressing different shRNA controls and a specific sequence for XBP-1. UPRE-
Luciferase construct and a plasmid containing β-galactosidase (as a transfection control) were transiently transfected in HT1080 cells.
UPRE reporter was induced with 4 μg/ml of tunicamycin (Tm) for 8 hours. We used HT1080 cells stably expressing a shRNA sequence
specific for XBP-1 (shXBP-1HT1080) and four control sequences as follows: a sequence with four mismatches from the original shRNA-
specific sequence for XBP-1 (shMM-HT1080); a nontarget sequence (shNT-HT1080); a sequence from GFP (shGFP-HT1080); and pBabe
empty vector–expressing cells (HT1080-pBabe). Error bars, SE of the mean from a triplicate.
Figure W3. VEGF secretion assay in media conditioned during
24 hours of normoxia or hypoxia (O2 < 0.02%). There was no differ-
ence in VEGF secretion between Su.86.86 shRNA scramble control
cells (shSc.Su.86.86) and cells expressing a specific short-hairpin
sequence for XBP-1 (shXBP-1Su.86.86). Error bars, SD.
